FDA rejects a biotech’s kidney drug, but some analysts still see a ‘sliver of hope’
The FDA's decision wasn't surprising to analysts, as "deficiencies" in an approval application have become somewhat of a prelude to rejection. This year alone saw two...
Continue Reading →
